Rhythm Pharmaceuticals Inc
Closed
SectorHealthcare
104.62 2.4
Overview
Share price change
24h
Min
103.67
Max
106.1
Income | -49M -105M |
|---|---|
Sales | 11M 71M |
EPS | -0.73 |
Profit margin | -147.27 |
Employees | 414 |
EBITDA | 6.2M -44M |
Next Earnings | 3 Nov 2026 |
|---|
Market Cap | 24M 7.1B |
|---|---|
Previous open | 102.22 |
Previous close | 104.62 |
News Sentiment
By Acuity
64%
36%
285 / 339 Healthcare
Rhythm Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Rhythm Pharmaceuticals Inc Forecast
Sentiment
By Acuity
285 / 339 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.